This review synthesizes the available materials to map the worldwide competitive set in urothelial bladder cancer (UBC), comparing major modalities, segmenting by disease setting and line of therapy, and identifying phase leaders and whitespace by biomarker subgroup. The dataset integrates sponsor pipelines, trial analyses, and targeted searches covering the US, EU, and China; in several areas, EU visibility is limited and select modalities (e.g., FGFR-selective programs and CAR-T) are under-represented in the retrieved materials 1218.
Executive Summary
- First-line metastatic disease has been reshaped by enfortumab vedotin plus pembrolizumab (EV+P), which more than doubled median OS versus platinum chemotherapy in EV-302 and set a new global standard across cisplatin-eligible and -ineligible populations 1315.
- Perioperative MIBC leadership is held by durvalumab combined with cisplatin/gemcitabine neoadjuvant and continued adjuvant durvalumab (NIAGARA), with significant EFS and OS benefits. Nivolumab + Gem/Cis also improved OS and PFS in cisplatin-eligible first-line metastatic disease (CheckMate 901) 17.
- In high-risk NMIBC, systemic PD-(L)1 plus BCG has shown clinical activity, but the requirement for BCG maintenance to achieve superior outcomes compared to BCG alone remains a key focus of ongoing investigations for combinations like sasanlimab + BCG and durvalumab + BCG. Novel intravesical platforms are advancing: TAR-200 has best-in-class papillary-only results in BCG-unresponsive NMIBC (SunRISe-1), an ongoing Phase 3 footprint, and an FDA-filed NDA; nadofaragene firadenovec is approved and now testing Phase 3 combinations (ABLE-22) 172324282916.
- ADC competition beyond EV is intensifying: Nectin-4 (BT8009; CRB-701), TROP2 (sacituzumab tirumotecan), and HER2 (RC48/vedicitumab) are in active clinical development across the US and China, including NMIBC intravesical formats and bladder-sparing/perioperative strategies 21819202324.
- Gaps in the retrieved materials include limited, current FGFR-selective (FGFR2/3) details and sparse CAR-T visibility; both remain whitespace and partnering opportunities 3410183132.
Modality/Format Mix and Phase Leaders
- ADCs and ADC–IO combinations dominate late-phase metastatic development (EV+P) and are expanding into bladder-sparing/perioperative spaces. Nectin-4 is the leading ADC target; HER2 and TROP2 are active challengers 13151819202324.
- ICIs anchor perioperative and NMIBC programs (e.g., durvalumab, sasanlimab) and remain foundational in metastatic combinations 17.
- FGFR TKIs (FGFR2/3) are essential precision strategies but were sparsely represented in the retrieved materials (examples: vepugratinib Phase 2 entry); broader class mapping requires additional registry interrogation 41031.
- Cell therapy is nascent in UBC; limited Phase I activity (e.g., CD70 CAR-T in China) and few visible active global programs signal whitespace 11822252627.
Selected Late-Phase and Notable Active Programs
Table 1. Representative clinical-stage programs (Phase 2/3 emphasis) by sponsor, asset, modality, setting, and status from the retrieved materials.
- Astellas/Pfizer: Enfortumab vedotin + Pembrolizumab (ADC Nectin-4 + PD-1), 1L LA/mUC, Phase 3: OS 31.5 vs 16.1 mo (HR 0.47); PFS 12.5 vs 6.3 mo (HR 0.45) in EV-302; ongoing bladder-sparing MIBC programs (NCT07566156 Phase 3; NCT06809140 Phase 2) 13181920.
- AstraZeneca: Durvalumab + GC neoadjuvant → adjuvant durvalumab (PD-L1 + chemo), perioperative MIBC, Phase 3 (NIAGARA): EFS HR 0.68; OS HR 0.75; significant pCR and ctDNA clearance improvements 17.
- BMS/Ono: Nivolumab + Gem/Cis (PD-1 + chemo), 1L cisplatin-eligible mUC, Phase 3 (CheckMate 901): OS 21.7 vs 18.9 mo (HR 0.78), PFS HR 0.72, higher CR rate 17.
- Pfizer: Sasanlimab + BCG (PD-1 + intravesical BCG), high-risk BCG-naïve NMIBC, Phase 3: EFS HR 0.68 with BCG induction + maintenance; induction-only arm negative 17.
- AstraZeneca: Durvalumab + BCG, high-risk BCG-naïve NMIBC, Phase 3: DFS benefit when BCG maintenance is included; induction-only arm negative 17.
- Johnson & Johnson: TAR-200 ± cetrelimab; intravesical gemcitabine-releasing system ± PD-(L)1, high-risk NMIBC Phase 3 programs; SunRISe-1 Cohort 4 (papillary-only, BCG-unresponsive) shows 6-mo DFS 85.3%, 9-mo DFS 81.1%, 9-mo PFS 95.6%; NDA submitted Jan 2025 623242829.
- Ferring: Nadofaragene firadenovec (intravesical gene therapy) approved for BCG-unresponsive NMIBC; ABLE-22 Phase 3 trial testing combinations to improve on ~51% 3-mo CR 1624.
- Bicycle Therapeutics: BT8009 (zelenectide pevedotin; Nectin-4 Bicycle toxin conjugate) + pembrolizumab, 1L cisplatin-ineligible mUC: ORR 65% (CR 25%); DCR 90%; DOR not reached (Phase I/II combo cohort) 2.
- Sichuan Kelun/Merck: Sacituzumab tirumotecan (SKB264; TROP2 ADC) monotherapy in refractory mUC: ORR 31% in urothelial cohort (n=49), manageable hematologic safety (Phase I/II) 2.
- Corbus/CSPC: CRB-701 (Nectin-4 ADC) early Phase I/II dose escalation; preliminary activity, no DLTs, suggested PK advantages including potentially longer half-life or different toxicokinetic profiles compared to EV; UBC-specific outcomes not yet delineated 2.
- Mabwell: 9MW-2821 (Nectin-4 ADC) + teriprinalimab in 1L LA/mUC (China); registrational activity, broad Phase 1–3 program; positioning as a Nectin-4 competitor to EV 1821.
- Hengrui: SHR-A2102 (Nectin-4 ADC, TOPO1i payload); Breakthrough Therapy Designation in China post–platinum/PD-(L)1 failure; advancing across multiple Phase 1–3 trials 18222627.
- Remegen/Zai Lab (China): Disitamab vedotin (RC48; HER2 ADC) intravesical Phase 1 in HER2-expressing NMIBC (BCG-naïve/unresponsive) and RC48 + tislelizumab Phase 2 perioperative bladder-preserving MIBC (China) 518.
- NIH-coordinated: MODERN (NCT05987241), ctDNA-guided nivolumab ± relatlimab after surgery for MIBC; Phase 2/3 biomarker-driven perioperative immunotherapy 1830.
- FGFR inhibitors: Vepugratinib (LY3866288) Phase 2 includes bladder cancer; broader FGFR2/3 program details limited in retrieved materials 4103132.
Detailed Modality Comparisons
-
ADCs (Nectin-4, TROP2, HER2):
- EV+P is practice-changing in 1L LA/mUC with OS and PFS benefit versus chemotherapy and favorable overall tolerability despite higher neuropathy and skin events (class-related) 1315.
- BT8009 + pembrolizumab demonstrates strong first-line activity in cisplatin-ineligible mUC (ORR 65%, CR 25%) with early follow-up; peripheral neuropathy remains notable 2.
- Sacituzumab tirumotecan shows meaningful monotherapy activity in heavily pretreated mUC (ORR 31%); toxicities are predominantly hematologic, in line with TOPO1i ADCs 2.
- CRB-701 shows early signals of activity with favorable PK/safety; UBC efficacy segmentation pending 2.
- Chinese Nectin-4 competitors (9MW-2821, SHR-A2102) and HER2 intravesical/combination strategies (RC48 ± tislelizumab) broaden competition across lines and modalities 182122265.
-
ICIs (monotherapy, chemo-IO, BCG-IO):
- Perioperative durvalumab (NIAGARA) improves EFS and OS when layered onto standard neoadjuvant chemotherapy and continued adjuvant, with higher pCR/ctDNA clearance, establishing a perioperative benchmark 17.
- Nivolumab + Gem/Cis improves survival versus chemotherapy alone in first-line cisplatin-eligible mUC (CheckMate 901) 17.
- NMIBC: PD-(L)1 plus BCG with maintenance improves EFS/DFS versus BCG alone; induction-only is insufficient, clarifying design principles for this setting 17.
-
FGFR TKIs (precision oncology):
-
Intravesical devices/biologics:
- TAR-200 has compelling papillary-only BCG-unresponsive efficacy and a Phase 3 footprint in BCG-naïve and BCG-unresponsive settings; NDA filed via RTOR, highlighting near-term regulatory potential 623242829.
- Nadofaragene firadenovec offers an approved option in BCG-unresponsive NMIBC and is now testing combinations in Phase 3 (ABLE-22) 1624.
-
CAR-T/cellular therapies:
Segmentation by Line of Therapy and Disease Setting
-
Non–muscle-invasive (NMIBC):
- BCG-naïve high-risk: Sasanlimab + BCG and durvalumab + BCG (both with BCG maintenance) improve time-to-event outcomes versus BCG alone; induction-only approaches do not 17.
- BCG-unresponsive: TAR-200 shows best-in-class papillary-only outcomes in SunRISe-1; nadofaragene firadenovec approved and pursuing combination improvements in Phase 3 ABLE-22 232416.
- Innovative intravesical ADCs: early intravesical RC48 (HER2 ADC) signals a differentiated format for NMIBC 18.
-
Muscle-invasive (MIBC)/Perioperative:
-
Metastatic/locally advanced:
- First-line: EV+P is the global benchmark with significant OS/PFS/ORR gains; nivolumab + Gem/Cis provides survival improvement in cisplatin-eligible patients 131517.
- Later lines: Sacituzumab tirumotecan demonstrates monotherapy activity in refractory mUC; early Nectin-4 ADCs (CRB-701) and BTCs (BT8009) show promise 2.
Why These Programs Lead
- EV+Pembrolizumab continues to lead in 1L LA/mUC due to robust, consistent OS and PFS advantages, high response and CR rates, and acceptable safety compared with chemotherapy 1315.
- Durvalumab perioperative strategy (NIAGARA) leads in MIBC by delivering dual endpoint wins (EFS, OS) and improved pCR/ctDNA clearance over chemo alone, reinforcing the value of ICI across the perioperative continuum 17.
- PD-(L)1 + BCG with maintenance leads in high-risk NMIBC by demonstrating clear incremental benefit versus BCG alone; consistent negative induction-only results provide a mechanistic and design framework for success 17.
- TAR-200 is the leading intravesical device-drug platform with strong papillary-only outcomes and an active registrational path 23242829.
Biomarker Subgroups and Whitespace
- Nectin-4: EV+P efficacy is established in unselected first-line populations; heterogeneity by Nectin-4 levels is not defined in the retrieved materials. BT8009 reports higher activity in NECTIN4-amplified subsets in non-UBC cohorts, suggesting a hypothesis for UBC enrichment pending dedicated data 21315.
- HER2: RC48 programs (including intravesical and perioperative bladder-sparing combinations) point to a HER2-enriched perioperative/NMIBC niche, especially in China 518.
- TROP2: Sacituzumab tirumotecan shows activity in refractory mUC; TROP2 expression–linked enrichment is referenced across tumor types, though UBC-specific biomarker stratification was not supplied 2.
- FGFR2/3 alterations: Recognized as a critical UBC subset, but detailed current Phase 2/3 program mapping is incomplete in the retrieved materials beyond a vepugratinib trial entry, representing a major whitespace for precision oncology 4103132.
- MRD (ctDNA): MRD-guided perioperative strategies are emerging (e.g., MODERN; atezolizumab ctDNA paradigms referenced), with de-escalation potential in MRD-negative patients and need for randomized validation in MRD-positive cohorts 1718.
- CAR-T: Limited visibility of active UBC-directed CAR-T trials (only a Phase I CD70 CAR-T in China noted), marking substantial whitespace for antigen-targeted cell therapy (e.g., Nectin-4, HER2, TROP2, FGFR3) 118.
Notable Combination Strategies and Near-Term Readouts
- ADC + ICI: EV+P remains the anchor in first-line metastatic; bladder-sparing Phase 2/3 trials could extend this platform to organ-preserving strategies 181920.
- Intravesical + ICI: TAR-200 ± cetrelimab (Phase 3) explores additive benefit to intravesical sustained-release chemotherapy; registrational momentum is high (NDA submitted) 23242829.
- PD-(L)1 + BCG maintenance: Multiple late-phase programs converge on efficacy with maintenance; this will likely shape standards of care in high-risk NMIBC 17.
- Perioperative biomarker guidance: MODERN’s ctDNA-guided nivolumab ± relatlimab represents a sophisticated approach that may define the future of adjuvant immunotherapy personalization 18.
- Chinese ADCs: 9MW-2821 and SHR-A2102 are positioned for competitive entries in Nectin-4 with Phase 3 development and regulatory designations, potentially impacting first-line metastatic choices, particularly in China 1821222627.
Sponsor-Level Map (selected)
- Astellas/Pfizer: EV+P leadership in 1L mUC; bladder-sparing MIBC trials in Phase 2/3 13181920.
- AstraZeneca: Durvalumab perioperative leader; durvalumab + BCG in NMIBC with maintenance benefit 17.
- BMS/Ono: Nivolumab + chemotherapy 1L cisplatin-eligible mUC; ctDNA-guided programs via MODERN framework (nivolumab ± relatlimab) 1718.
- Johnson & Johnson: TAR-200 ± cetrelimab in NMIBC (Phase 3) and SunRISe-1 Cohort 4 data; cetrelimab PD-(L)1 programs 162324.
- Ferring: Nadofaragene (approved) with Phase 3 combo expansion (ABLE-22) 1624.
- Bicycle Therapeutics: BT8009 (Nectin-4 BTC) in mUC combinations with pembrolizumab 2.
- Sichuan Kelun/Merck: Sacituzumab tirumotecan monotherapy activity in refractory mUC; multi-tumor program 2.
- Corbus/CSPC: CRB-701 early Nectin-4 ADC signals 2.
- Mabwell and Hengrui (China): Nectin-4 ADCs (9MW-2821, SHR-A2102) with breakthrough/registrational positioning 1821222627.
- Remegen/Zai Lab: RC48 intravesical NMIBC and RC48 + tislelizumab bladder-preserving MIBC strategies 518.
Unmet Needs and Strategic Whitespaces
- FGFR2/3: The precision oncology backbone for molecularly defined UBC remains under-detected in the retrieved dataset; mapping selective FGFR programs and perioperative applications is a high-value opportunity 4103132.
- CAR-T: Sparse clinical activity in UBC; a fertile space for innovation in antigen selection and trafficking to urothelial tumors 118.
- Post-EV resistance: Limited cross-modality strategies beyond PD-(L)1 and chemo; HER2 and TROP2 ADCs, or ADC + targeted combinations (e.g., FGFR inhibitors), represent logical development avenues referenced as whitespace in the search synthesis 18.
- MRD-guided perioperative algorithms: Prospective validation in MRD-positive cohorts and standardization of ctDNA assays remain essential next steps 1718.
- NMIBC optimization: Head-to-head comparisons among PD-(L)1 + BCG combinations, best BCG schedules, and positioning versus intravesical gene therapy or device-based delivery are not yet settled 172324.
Bottom Line
- EV+Pembrolizumab has set a global standard in first-line metastatic UBC with unprecedented survival gains and high response rates 1315.
- Durvalumab-based perioperative chemo-IO leads in MIBC by improving both EFS and OS, while nivolumab + Gem/Cis solidifies first-line benefit in cisplatin-eligible metastatic disease 17.
- For NMIBC, PD-(L)1 + BCG requires maintenance to meaningfully outperform BCG alone; device-enabled and gene therapy intravesical platforms (TAR-200, nadofaragene) are reshaping the bladder-sparing treatment space with strong data and active registrational strategies 172324282916.
- ADC competition is intensifying across Nectin-4, HER2, and TROP2 with US/EU/China programs, while FGFR-selective and CAR-T approaches remain underrepresented in the retrieved materials—key whitespaces for future investment and partnering 21821222643132.
Where detailed EU and selective FGFR/CAR-T program data were not found in the retrieved materials, those gaps are flagged explicitly above to guide targeted follow-up research and partnering outreach 1218.